Bluejay Diagnostics, Inc. (BJDX) has seen a push of 9.03% in the premarket despite any latest news. However, the last trading session closed at $1.55 with a decrease of 8.28%.
Completion of 90 Subjects in Multicenter Clinical Study
BJDX announced on 13th January 2022 that in a randomized multicenter clinical trial targeting the fast IL-6 test for COVID-19 patients receiving critical care, 90 subjects were completed. This research uses patient whole blood to produce a unique quick on-site measurement, allowing the company to move forward with a number of activities. Early detection of this susceptible patient population can aid medical care in the implementation of preventative measures. Furthermore, employing IL-6 as an early warning indicator can help healthcare systems save lives by allowing them to sequester crucial resources in time.
What’s Next?
This stage of clinical research is critical not just for licensing, but also for demonstrating the Symphony System’s comparative edge in medical care. With all these studies, BJDX will move forward on a range of projects that will emphasize the relevance of IL-6 screening.
Appointment of Mark Feinberg – Worth it?
On 5th January 2022, BJDX announced that Mark Feinberg has been appointed as the Chief Medical Advisor. Dr. Feinberg will oversee Bluejay’s clinical development activities and serve as the company’s research and biological advisor. Moreover, the company is glad to introduce Mark to the role of Chief Medical Advisor. BJDX believes that Mark’s significant medical context and corporate strategy leadership ability will be extremely valuable. Lastly, BJDX plans to file its Symphony IL-6 Test Pre-Submission application with the FDA in January 2022.
Third Quarter 2021 Financial Results
BJDX reported third-quarter 2021 financial results on 16th December 2021. The company reported that research and development expenses came out to be $442,527. Moreover, general, and administrative expenses were $445,050 and net loss totaled $1,193,381. Last but not the least, the company experienced cash and cash equivalents of $2,330,138.
